Abstract

Protein tyrosine phosphatase 1B (PTP1B) has been demonstrated to play a key role in the negative signaling pathway of insulin. Potent and orally active PTP1B inhibitors are considered to be promising pharmacological agents for the treatment of type 2 diabetes and resistance to weight gain. CoMFA studies were performed on a set of PTP1B inhibitors, which are known to bind simultaneously to the active site as well as a sub-binding site. An alignment, based on eight different crystal structure complexes of PTP1B was carried out to study the synergistic application of the alignment on CoMFA. The CoMFA model with statistical parameters \( r_{\text{cv}}^{ 2} = 0. 50 6,\;r_{\text{ncv}}^{ 2} = 0. 9 8 5 \), standard error of estimate 0.12, and F = 244.4 was found to be significant. The steric and electrostatic components presumably play an important role to achieve activity and selectivity in this series of molecules.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.